Breaking News, Collaborations & Alliances

Samsung Biologics and LegoChem Sign ADC Partnership Agreement

Samsung Biologics to provide antibody development and drug substance manufacturing services as a part of LegoChem Biosciences' ADC program.

Author Image

By: Charlie Sternberg

Associate Editor

Samsung Biologics, a global contract development and manufacturing organization (CDMO), has signed a partnership agreement with LegoChem Biosciences, a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.   Under the terms of the deal, Samsung Biologics will provide antibody development and drug substance manufacturing services as a part of LegoChem Biosciences’ ADC program designed to treat solid tumors.   LegoChem Biosciences aims to subm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters